ATE449078T1 - 5-ht7 rezeptor-antagonisten - Google Patents

5-ht7 rezeptor-antagonisten

Info

Publication number
ATE449078T1
ATE449078T1 AT01928857T AT01928857T ATE449078T1 AT E449078 T1 ATE449078 T1 AT E449078T1 AT 01928857 T AT01928857 T AT 01928857T AT 01928857 T AT01928857 T AT 01928857T AT E449078 T1 ATE449078 T1 AT E449078T1
Authority
AT
Austria
Prior art keywords
disorders
receptor antagonists
amino
schizophrenia
anxiety
Prior art date
Application number
AT01928857T
Other languages
English (en)
Inventor
Michael Poss
Ashok Purandare
Ronald Mattson
Li-Qiang Sun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE449078T1 publication Critical patent/ATE449078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
AT01928857T 2000-05-09 2001-04-25 5-ht7 rezeptor-antagonisten ATE449078T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20293100P 2000-05-09 2000-05-09
PCT/US2001/013324 WO2001085701A1 (en) 2000-05-09 2001-04-25 5-ht7 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE449078T1 true ATE449078T1 (de) 2009-12-15

Family

ID=22751788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928857T ATE449078T1 (de) 2000-05-09 2001-04-25 5-ht7 rezeptor-antagonisten

Country Status (9)

Country Link
US (1) US6630469B2 (de)
EP (1) EP1280781B1 (de)
JP (1) JP2003532714A (de)
AT (1) ATE449078T1 (de)
AU (1) AU2001255669A1 (de)
CA (1) CA2409729A1 (de)
DE (1) DE60140530D1 (de)
ES (1) ES2334491T3 (de)
WO (1) WO2001085701A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE511858T1 (de) * 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
EP1727806A1 (de) * 2004-01-16 2006-12-06 Novartis AG 2,4-diaminopyrimidine und deren verwendung bei der induktion von kardiomyogenese
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
CN103951658B (zh) * 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
AU2011212930B2 (en) 2010-02-04 2016-02-11 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
WO2012003476A2 (en) * 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
CN102389744B (zh) * 2011-09-09 2013-08-21 大连理工大学 一类均三嗪两性甜菜碱表面活性剂及其合成方法
WO2014019023A1 (en) 2012-08-01 2014-02-06 Bionomics Limited α7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
EP3610890A1 (de) 2012-11-14 2020-02-19 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von schizophrenie
ES2889876T3 (es) 2015-01-29 2022-01-14 Univ Illinois Ciclopropilmetanaminas como agonistas selectivos del receptor 5-HT(2C)
MX2018011453A (es) 2016-03-22 2019-01-10 Merck Sharp & Dohme Moduladores alostericos de receptores de acetilcolina nicotinicos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1288903A (de) 1971-04-16 1972-09-13
BE792914A (fr) 1971-12-18 1973-06-18 Schering Ag Derives amino de n-heterocycles et leur procede de preparation
US3816629A (en) 1972-09-01 1974-06-11 Kyorin Seiyaku Kk 2-amino-4,6-diphenethylamino-s-triazine for treating arteriosclerosis
DE3717480A1 (de) 1987-05-23 1988-12-01 Shell Agrar Gmbh & Co Kg Neue herbizid und mikrobizid wirksame 2,6-diaminopyrimidine
DK0580753T3 (da) 1991-04-17 1995-07-03 Pfizer Pyrimidinderivater til forøgelse af antitumoraktivitet
US5491234A (en) 1992-03-30 1996-02-13 Pfizer Inc. Pyrimidine derivatives for enhancing antitumor activity
DE19531084A1 (de) * 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US6117996A (en) 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
JP3967783B2 (ja) 1996-07-31 2007-08-29 富士フイルム株式会社 顔料分散組成物及びそれを用いた着色感光性組成物
DE19641694A1 (de) 1996-10-10 1998-04-16 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine
DE19704922A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JP2002515408A (ja) 1998-05-19 2002-05-28 アルコン ラボラトリーズ， インコーポレーテッド 眼および中枢神経系疾患治療用セロトニン作動性５ｈｔ７受容体化合物

Also Published As

Publication number Publication date
WO2001085701A1 (en) 2001-11-15
JP2003532714A (ja) 2003-11-05
EP1280781A4 (de) 2003-08-06
EP1280781B1 (de) 2009-11-18
ES2334491T3 (es) 2010-03-11
US20020032199A1 (en) 2002-03-14
CA2409729A1 (en) 2001-11-15
US6630469B2 (en) 2003-10-07
EP1280781A1 (de) 2003-02-05
AU2001255669A1 (en) 2001-11-20
DE60140530D1 (de) 2009-12-31

Similar Documents

Publication Publication Date Title
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
DE60334015D1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60234116D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
CY1106165T1 (el) Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης
ATE449078T1 (de) 5-ht7 rezeptor-antagonisten
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
ATE259230T1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
NO994850L (no) Farmakologiske midler
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
ATE292107T1 (de) Verwendung von carbonylaminoderivaten gegen zentralnervensystem-störungen
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties